Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

2022 Access to Medicine Index

The 8th Access to Medicine Index provides detailed insights into how 20 of the world's leading pharmaceutical companies perform on ensuring people living in low- and middle-income countries have access to the medicines, vaccines and diagnostics they need.

Date

15 November 2022

Read the full report

Every two years, the Index assesses companies on their performance on priority access-to-medicine topics, while identifying best practices and examples, and highlights areas where progress has been made and areas where critical action is required.

The 2022 Index looks at companies' products and R&D projects for 83 diseases, conditions and pathogens that have been identified as the most critical priorities regarding access to medicine. These 20 companies are assessed, scored and ranked based on 31 metrics spanning R&D, governance, pricing and supply.

What's in the 2022 report?

2022 Ranking

GSK retains the No.1 spot, followed closely by Johnson & Johnson. AstraZeneca has newly joined the top 3 and Merck the top 5. GSK leads by tailoring access strategies across products and engaging in R&D to develop treatments for diseases that disproportionally affect people living in LMICs.

3 Key Findings

The three most significant findings of the report, including insights on the R&D pipeline for emerging infectious diseases; promising signs in how companies are engaging in voluntary licensing; and access plans and strategies companies are using – or not using – to expand access to more products.

20 Report cards

Detailed performance breakdown for each company, featuring key opportunities for improvement.

19 Best Practices

The strongest actions that pharmaceutical companies are currently taking to enhance access to medicine.

3 Special Reports

Cross-cutting analyses focused on COVID-19 & pandemic preparedness; longitudinal analysis of the industry's performance over time; and women's sexual and reproductive health rights (SRHR).

Companies approach access to medicine more systematically, yet show stagnation in some key areas

The Index finds progress in how companies are integrating access to medicine into governance structures, R&D processes, and monitoring efforts. However, despite this progress, low-income countries are still widely overlooked.

"The 2022 Index finds that industry-wide improvement in planning for access and expanding access strategies still overlooks low-income countries. Companies must consider the depths of their plans, strength of their supply chains, and equity of their pricing strategies to reach the most vulnerable populations."

James Hazel

Research Programme Manager for the 2022 Index, Access to Medicine Foundation

Resource Center

Explore the findings from 2022 Access to Medicine Index

More access plans and strategies to expand access to more products, but with limited breadth and depth

15 November 2022

First voluntary licence for a cancer treatment is a promising sign for future expansion of access to innovative medicines

15 November 2022

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved